Media headlines about Cynosure (NASDAQ:CYNO) have trended positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cynosure earned a news impact score of 0.26 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 46.85 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

ILLEGAL ACTIVITY NOTICE: “Cynosure (CYNO) Receiving Positive News Coverage, Analysis Finds” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://theolympiareport.com/2017/11/02/cynosure-cyno-receiving-positive-news-coverage-analysis-finds.html.

Cynosure Company Profile

Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.

Insider Buying and Selling by Quarter for Cynosure (NASDAQ:CYNO)

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.